High expression of RUNX1 in colorectal cancer subtype accelerates malignancy by inhibiting HMGCR
Open Access
- 4 July 2024
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 206, 107293
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- RUNX transcription factors: biological functions and implications in cancerClinical and Experimental Medicine, 2024
- Single‐cell characteristics and malignancy regulation of alpha‐fetoprotein‐producing gastric cancerCancer Medicine, 2023
- RUNX1 and cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022
- Metformin inhibition of colorectal cancer cell migration is associated with rebuilt adherens junctions and FAK downregulationJournal of Cellular Physiology, 2020
- RUNX1-activated upregulation of lncRNA RNCR3 promotes cell proliferation, invasion, and suppresses apoptosis in colorectal cancer via miR-1301-3p/AKT1 axis in vitro and in vivoClinical and Translational Oncology, 2020
- Runx1 Role in Epithelial and Cancer Cell Proliferation Implicates Lipid Metabolism and Scd1 and Soat1 ActivityStem Cells, 2018
- Predictive value of blood lipid association with response to neoadjuvant chemoradiotherapy in colorectal cancerTumor Biology, 2015
- Microsatellite Instability Testing and Its Role in the Management of Colorectal CancerCurrent Treatment Options in Oncology, 2015
- p53 and Cell Cycle Effects After DNA Damage2012
- The ubiquitin-proteasome system in colorectal cancerBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2008